Indication
Treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy.
Medicine details
- Medicine name:
- bimekizumab (Bimzelx)
- SMC ID:
- SMC2698
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Publication due date:
- 07 April 2025
- SMC meeting date:
- 04 March 2025
- Patient group submission deadline:
- 02 September 2024